Most Popular Stories
Poll
Featured Jobs
-
South Carolina Orthopedic Surgeon
StaffPointe, LLC - northeast, SC -
Missouri Hematologist/Oncologist
StaffPointe, LLC - southeast, MO -
New Jersey PA or NP
StaffPointe, LLC - northeast, NJ -
New York Pediatrician
StaffPointe, LLC - east, NY -
Florida Med Peds
StaffPointe, LLC - Panhandle , FL
Events
- World Healthcare Innovation & Technology Congress WHIT v.4.0
Dec 8-10 — Washington, DC - World Health Care Congress
April 14-16, 2009 — Washington, DC
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Popular Topics
SPOTLIGHT: Pharmas focusing on pet psych meds
July 13, 2008 — 12:18pm ET | By Anne Zieger
Did you ever think your dog could suffer from dementia, OCD or an anxiety disorder? Apparently, pharmaceutical giants like Pfizer, Eli Lilly and Novartis do. The drugmakers are dishing out human psychiatric drugs to dogs whose behavior mimics human mental illnesses. What's more, this may be just the start of the pet psych meds business. Sounds like a golden (retriever) opportunity! FiercePharma
Be the first to comment
Related Stories
- FDA investigates blindness link in Viagra
- Cephalon settlement requires physician payments to be disclosed
- Pfizer gets into stem cell research
- Medicare overpaid for prescription drugs with generic versions
- FDA panel votes against black box for epilepsy meds
- Drugmakers agree to six-month DTC delay
- Harvard psychiatrists fail to reveal millions in pharma pay
- ALSO NOTED: FDA sending fewer warning letters;IL law would limit what hospitals can charge uninsured patients; and much more...
- ALSO NOTED: MD group wants pay for online work; Lilly working out its Zyprexa problem; and much more...
- Eli Lilly to pay $62M to settle Zyprexa marketing charges
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





